ImmunityBio (IBRX) Gross Profit (2023 - 2026)

ImmunityBio (IBRX) has 4 years of Gross Profit data on file, last reported at $44.0 million in Q1 2026.

• Gross Profit for Q1 2026 came in at $44.0 million, up 167.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $140.0 million (up 349.38% YoY), and the FY2025 annual result was $112.5 million, up 663.21% from the prior year.
• Gross Profit improved to $44.0 million in Q1 2026 per IBRX's latest filing, from $37.9 million in the prior quarter.
• Over five years, Gross Profit peaked at $44.0 million in Q1 2026 and troughed at $40000.0 in Q1 2024.
• A 4-year average of $14.3 million and a median of $6.8 million in 2024 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2025 and 2026: Gross Profit surged 41047.5% in 2025, then surged 167.14% in 2026.
• A 4-year view of Gross Profit shows it stood at $139000.0 in 2023, then soared by 5333.09% to $7.6 million in 2024, then soared by 401.89% to $37.9 million in 2025, then increased by 16.0% to $44.0 million in 2026.
• Business Quant data shows IBRX's Gross Profit at $44.0 million in Q1 2026, $37.9 million in Q4 2025, and $31.9 million in Q3 2025.